To the editor: We have read with interest the recent paper by Kubanova et al. in which they recommend the use of spectinomycin in case of difficulty to access ceftriaxone or in the presence of severe beta-lactam antimicrobial allergy [1]. Although we agree with most of the conclusions we would like to warn about the potential risks in cases of pharyngeal gonorrhoea. Spectinomycin is an aminoglycoside with poor saliva excretion. Probably due to changes in sexual behaviours the number of pharyngeal carriers of Neisseria gonorrhoeae is not anecdotal - papers report figures between 6% to 14% [2]. Moreover oral sex as only risk factor for urethral gonorrhoea is high ranging from 10% to 58% [2]. Lack of effective eradication of Neisseria gonorrhoeae from the pharynx with spectinomycin has been previously reported [3]. The Centers for Disease Control and Prevention (CDC) recommendations state that spectinomycin is useful for the treatment of patients who cannot tolerate cephalosporins and quinolones [4]. However, in the same guideline they recommended the use of a single dose of ceftriaxone, 125 mg intramuscularly, or 500 mg of oral ciprofloxacin (except for cases where high quinolone resistance is suspected) for pharynx eradication since spectinomycin is unreliable against pharyngeal infections. When spectinomycin is used, a pharyngeal negative culture three to five days after treatment should be the result [4]. In contrast, a single dose of two grammes of oral azithromycin would be considered an effective choice to cure non-complicated gonorrhoea from cervix, urethra and rectum and to eradicate the bacteria from the pharynx [5].

In conclusion we would point out that the use of a single dose of spectinomycin, though effective in the treatment of uncomplicated gonococcal infections from the cervix, urethra, and rectum, is less effective in the eradication of gonococci from the pharynx, thus allowing an important route for transmission of disease.

References